News | January 10, 2024
Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
US FDA approval based on NEURO-TTRansform Phase III results
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Subscribe To Our Newsletter & Stay Updated
